Recipharm and Medspray Announces Joint Venture

Pharma Tech Outlook: Pharma Tech Magazine

Recipharm and Medspray Announces Joint Venture

By Pharma Tech Outlook | Tuesday, February 16, 2021

Recipharm and Medspray launch Resyca joint Venture to exploit new Softmist technology for pharmaceutical applications.

FREMONT, CA: Recipharm AB (publ) (Recipharm), a pioneering contract development and manufacturing organization (CDMO) and Medspray BV (Medspray), a manufacturer of spray nozzles, trumpet that they have now completed the previously announced joint venture and established Resyca BV. Resyca will build and exploit the softmist spray nozzle technology for pharmaceutical use cases. This can eliminate propellants' requirement by offering therapies deep into the lungs effectively with lower doses as fewer results in the mouth and throat.

Recipharm AB is seeing some excellent traction in this field and has already signed an agreement with many more in the pipeline. The fit with Recipharms broader inhalation efforts is very clear and is part of its strategy to be among the leading integrated device development and manufacturing provider. The partnership with Recipharm cements the exciting opportunities it sees for the softmist spray nozzle technology in pharmaceutical applications. The potential benefits to both patient and environment make a highly compelling case for its adoption.

Recipharms investment in Resyca has been made through its subsidiary Recipharm BV. Resyca will run development facilities in Munich, Germany, and spray nozzles exclusively from Medspray in the Netherlands. It is expected that the commercial supply of finished devices will be manufactured and supplied by other Recipharm affiliates, including the specialist device manufacturing potentials located in Kings Lynn, UK. Additionally, Recipharm will get an exclusive license to offer its customers the development and manufacturing of syringe-based devices utilizing the softmist nozzle technology. These devices will be marketed under the brand Bespak by Recipharm.

Weekly Brief


Read Also